氯法齐明治疗耐多药结核病有效性与不良反应的研究进展

Research progress on the effectiveness and adverse reactions of clofazimine in the treatment of multidrug-resistant tuberculosis

氯法齐明是治疗耐多药结核病领域中老药新用的代表性药品,可有效增加耐多药结核病的痰菌阴转率、病灶吸收率及空洞缩小率,且不增加药物不良反应发生率,是世界卫生组织推荐治疗耐多药结核病的重要药品。作者对氯法齐明治疗耐多药结核病的临床有效性和不良反应进行简要综述,旨在为临床用药和临床研究提供参考。

Clofazimine is a representative repurposed drug in the field of multidrug-resistant tuberculosis(MDR-TB).Clofazimine can effectively increase the sputum negative conversion,lung lesion absorption,and cavity reduction of MDR-TB,without increasing the incidence of adverse reactions.It is an important drug recommended by the WHO guidelines.We briefly reviewed the clinical application progress and adverse reaction management of clofazimine in the treatment of MDR-TB,in order to provide references for clinical medication and clinical research.